Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.
Tetsu TomonariYasushi SatoHironori TanakaTakahiro TanakaTatsuya TaniguchiMsasahiro SogabeKoichi OkamotoHiroshi MiyamotoNaoki MugurumaTetsuji TakayamaPublished in: JGH open : an open access journal of gastroenterology and hepatology (2020)
Treatment with SOR may be effective for u-HCC after failure on LEN and may not worsen the liver reserve.